Procuring Native Natural Product Producers by In Situ Chimera Assembly

描述(申请人提供)：由于病原体耐药性的增加，由传染病引起的死亡呈上升趋势。因此，迫切需要开发新的抗生素来对抗抗药性感染。从历史上看，细菌一直是新的抗生素支架的最重要来源，展示了产生抗菌化合物的令人难以置信的能力。令人震惊的是，所有现有的以天然产品为基础的细菌衍生抗生素都来自地球微生物多样性中极其微小的一部分。具体地说，目前只有大约1%的细菌是可培养的，这意味着社会上所有最有价值的抗生素发现都来自确定的少数细菌分类群。已经提出并被元基因组研究证实，尚未培养的99%的细菌含有大量有待发现的潜在抗生素物质。然而，目前从未培养细菌中挖掘这些化合物的方法带来了许多挑战，严重阻碍了有效开采这一资源的努力。考虑到这些局限性，这一提议提出了一个新的假设，即尚未培养的细菌缺乏使可培养微生物在实验室中生存和繁殖的基因和基因产物。为了验证这一假设，我们团队正在开发一种创新技术，通过将实验室中生长强劲的细菌的基因组DNA大片段引入尚未培养的细菌中，创建可培养的嵌合体克隆。这些拟议的研究将通过四个具体目标来实现。AIM1包括用细菌人工染色体(BAC)文库将未培养的细菌原位导入土壤和沉积物中，该文库由易于培养的革兰氏阳性细菌的基因组DNA组成，并筛选新的(以前未培养的)嵌合克隆。AIM 2旨在测试BAC编码基因的表达，确定基因插入如何促进生长，并评估产生抗菌次级代谢物的微生物。Aim 3将提供另外两个BAC文库，其中包含一株革兰氏阳性高GC细菌的基因组DNA，以及一株基本上未培养但数量丰富的酸性细菌的代表，用于进一步的嵌合体生成研究。Aim 4将测试这种方法从海洋无脊椎动物样本中产生嵌合克隆的能力，以便有针对性地采购两类抗感染天然产品的未培养微生物生产者。作为这项研究的结果，预计会有几个重要的结果。重要的是，我们将为使用这项创新技术培养以前未培养的细菌并获得具有生物活性的天然产品奠定基础。此外，我们预计一些新获得的化合物将包括不寻常的支架，这些支架不是现有可培养细菌中遇到的。从长远来看，我们预计，来自以前未培养的细菌的新的天然产品将提供大量机会，以获得迫切需要的新型抗菌剂，以控制因抗生素耐药感染而造成的越来越多的人类生命损失。

DESCRIPTION (provided by applicant): Deaths due to infectious diseases are on the rise fueled largely by an increase in pathogen drug resistance. Accordingly, there is a critical need for the development of new antibiotics to combat antimicrobial-resistant infections. Historically, bacteria have served as the foremost source of new antibiotic scaffolds demonstrating an incredible capacity for generating antimicrobial compounds. Shockingly, all existing natural-product-based bacterial-derived antibiotics have come from an extremely minor fraction of the Earth's microbial diversity. Specifically, only about 1% of bacteria are currently culturable meaning that all of society's most valuable antibiotic discoveries have originated from a decided minority of bacterial taxa. It has been proposed and substantiated by metagenome studies that the yet uncultured 99% of bacteria harbor an abundance of potential antibiotic substances awaiting discovery. However, current methods for unearthing these compounds from uncultured bacteria pose numerous challenges that severely hamper efforts to effectively mine this resource. Considering these limitations, this proposal poses the novel hypothesis that yet uncultured bacteria lack the genes and gene products that enable culturable microbes to survive and proliferate in the lab. To test this hypothesis, our group is developing an innovative technology for creating culturable chimeric clones by introducing large fragments of genomic DNA from bacteria exhibiting robust growth in the lab into as of yet uncultured bacteria. These proposed studies will be accomplished by means of four specific aims. Aim1 involves carrying out the in situ transfection of uncultured bacteria in soils and sediments with a bacterial artifical chromosome (BAC) library composed of genomic DNA from a readily culturable Gram-positive bacterium and selecting for new (previously uncultured) chimeric clones. Aim 2 is designed to test for the expression of BAC encoded genes, identify how the gene inserts enable growth, and assess microbes for the production of antimicrobial secondary metabolites. Aim 3 will provide two additional BAC libraries containing genomic DNA from a Gram-positive high-GC bacterium and a representative of the largely uncultured, but abundant Acidobacteria for further chimera-generation studies. Aim 4 will test the capacity of this method to generate chimeric clones from marine invertebrate samples for the targeted procurement of uncultured microbial producers of two classes of antiinfective natural products. Several important outcomes are anticipated as a result of this research. Importantly, we will establish a foundation for using this innovative technique to grow previously uncultured bacteria and obtain their bioactive natural products. In addition, we expect that some of the newly accessible compounds will include unusual scaffolds not encountered from existing culturable bacteria. In the long-term, we anticipate that new natural products from previously uncultured bacteria will provide abundant opportunities to procure novel antimicrobials that are desperately needed to control the increasing loss of human life attributable to antibiotic-resistant infections.